Serial Entrepreneur Launches MarkSkoda.com After Reversing Insulin-Dependent Diabetes

NASHVILLE, Tenn. - EntSun -- Mark A. Skoda, a serial entrepreneur with more than five decades of international business experience, today announced the launch of MarkSkoda.com, a digital platform for AI-assisted health optimization. The launch follows Skoda's documented reversal of insulin-dependent Type 2 diabetes and a validated 29-year biological age reduction — from 71 to 42 — achieved in 150 days through systematic natural intervention.

In July 2025, Skoda was fully insulin-dependent, weighed 265 pounds, and had been told his diabetes was permanent. On his 71st birthday, he initiated a six-pillar protocol: therapeutic intermittent fasting, precision nutrition with continuous glucose monitoring, progressive resistance training, evidence-based supplementation, sleep optimization, and behavioral architecture. He used Claude AI as a strategic thinking partner throughout, generating 57,000 words of documentation his Vanderbilt endocrinologist called "the most comprehensive I have ever seen."

More on EntSun News

• Nashville Artist C.M. James Announces Cross-Genre Album "Don't Label Me: I Am A Label. What's A Genre?"
• Spring Surge in 55+ Communities: What Buyers and Sellers Need to Know in 2026
• Jason Caras Launches The Caras Institute Following Successful Exit from IT Authorities
• Serina Damesworth Hired as Century Fasteners Corp. – Director of Quality
• National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP

Validated outcomes included HbA1c reduction from 7.4% to 6.0%, complete elimination of insulin, 56-pound body recomposition with preserved muscle mass, and 95%+ continuous glucose monitor time in range against a 70% clinical benchmark — representing an estimated $57,000–$108,000 in avoided pharmaceutical costs over five years.

MarkSkoda.com opens for waitlist registration immediately, offering a free Research Hub with six physician-reviewed documents including the full case study, AI white paper, and supplement protocol. Paid tiers include a self-directed digital program, guided one-on-one consulting, and corporate wellness speaking engagements.

"I treated my body the same way I have treated every complex problem in 50 years of business — as a system to be re-engineered. The results are documented, validated, and replicable." — Mark A. Skoda, Founder,

With 537 million adults affected by Type 2 diabetes globally and the GLP-1 drug market projected at $100 billion annually by 2030, Skoda's methodology offers a documented, physician-validated alternative to lifetime pharmaceutical dependency.

All outcomes achieved under physician supervision and validated by Vanderbilt University Medical Center. Not medical advice. Individual results may vary.